SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NorthStrive Biosciences Reports Preliminary EL-32 Combination Study Findings

The preclinical study with semaglutide identified a preliminary lean-mass finding at the highest EL-32 dose. The results are informing the next phase of development.

ELAB

Related stories